Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study
British Journal of Radiology · 2024
DOI: 10.1093/bjr/tqae096 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, 2024. Verfasst von Osman Melih Topcuoglu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Yeditepe University Hospitals, Kosuyolu 34718, Turkey. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Yttrium Radioisotopes, Liver Neoplasms, Embolization, Therapeutic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To compare the survival and objective response rate (ORR) of the patients receiving estimated tumour absorbed dose (ETAD) <140 Gy versus ETAD ≥140 Gy in patients with advanced chemorefractory colorectal carcinoma liver metastases (CRCLM) treated with yttrium-90 transarterial radioembolization (90Y TARE).
Methods
Between August 2016 and August 2023 adult patients with unresectable, chemorefractory CRCLM treated with 90Y TARE using glass particles, were retrospectively enrolled. Primary outcomes were overall survival (OS) and hepatic progression free survival (hPFS). Secondary outcome was ORR.
Results
A total of 40 patients with a mean age of 66.2 ± 7.8 years met the inclusion criteria. Mean ETAD for group 1 (ETAD <140 Gy) and group 2 (ETAD ≥140) were 131.2 ± 17.4 Gy versus 195 ± 45.6 Gy, respectively. The mean OS and hPFS for group 1 versus group 2 were 12 ± 10.3 months and 8.1 ± 9.3 months versus 9.3 ± 3 months and 7.1 ± 8.4 months, respectively and there were no significant differences (P = .181 and P = .366, respectively). ORR did not show significant difference between the groups (P = .432).
Conclusion
In real-world practice, no significant difference was found in OS, hPFS, and ORR between patients who received ETAD <140 Gy versus ETAD ≥140 Gy in patients with CRCLM, in this series. Advances in knowledge This study demonstrated that increased tumour absorbed doses in radioembolization may not provide additional significant advantage for OS and hPFS for patients with CRCLM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Yeditepe University Hospitals, Kosuyolu 34718, Turkey.
- Department of Nuclear Medicine, Yeditepe University Hospitals, Kosuyolu 34718, Turkey.
ORCID-Profile: Osman Melih Topcuoglu, Ayşegul Gormez, Nalan Alan
Zitieren
APA
Topcuoglu, O. M., Orhan, T., Gormez, A., & Alan, N. (2024). Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study. British Journal of Radiology. https://doi.org/10.1093/bjr/tqae096
Vancouver
Topcuoglu OM, Orhan T, Gormez A, Alan N. Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study. British Journal of Radiology. 2024. doi:10.1093/bjr/tqae096
BibTeX
@article{Topcuoglu2024,
author = {Topcuoglu, Osman Melih and Orhan, Tolga and Gormez, Ayşegul and Alan, Nalan},
title = {Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study},
journal = {British Journal of Radiology},
year = {2024},
doi = {10.1093/bjr/tqae096}
}
EUVIMED